Last reviewed · How we verify
NCT05294523
Rocuronium and Supramaximal Stimulation
NA trial testing Rocuronium priming dose in Neuromuscular Blockade in 300 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Taipei Medical University Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | other |
| Enrollment | 300 |
| Start date | 20 December 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Rocuronium priming dose
Conditions studied
- Neuromuscular Blockade — all drugs for Neuromuscular Blockade →
Sponsor
Taipei Medical University Hospital
Who can join
Adults 18 to 65, any sex, with Neuromuscular Blockade. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To shorten induction time, some anesthesiologist gives a priming dose of muscle relaxant before starting Neuromuscular Transmission monitor (NMT). To properly evaluate neuromuscular function during the surgury, baseline supramaximal stimulation of the monitored nerve is mandatory. Not knowing if the priming dose of muscle relaxant affects the supramaximal stimulation current setting, The investigators designed this study to find out.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05294523
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuromuscular Blockade
Currently open trials in the same condition.
- NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
- NCT06945341 — International Focus Group Discussion on Neuromuscular Monitoring. · recruiting
- NCT06948409 — NMBA Reversal and Postoperative Urinary Retention · active not recruiting
- NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
- NCT06679569 — Deep Neuromuscular Blockade on Postoperative Pain · NA · recruiting
Other Taipei Medical University Hospital trials
Trials by the same sponsor.
- NCT07294469 — Menthol for Improving Movement and Sleep in Parkinson's Disease Patients · Phase 2 · not yet recruiting
- NCT07114289 — Spontaneous Breathing Trials Using Pressure Support or T-Piece in Overweight and Obese Patients · NA · recruiting
- NCT06949618 — Repetitive Transcranial Magnetic Stimulation in Cancer Pain Management · NA · not yet recruiting
- NCT05830578 — Clinical Validation of the Electrocardiogram Measurement · unknown
- NCT05877079 — TRPM8 in Acute Ischemic Stroke by Topical Menthol · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05294523 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University Hospital
- Last refreshed: 29 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05294523.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing